A drug that boosts bone growth in children with achondroplasia may also reduce their chances of sudden infant death syndrome (SIDS), sleep apnoea and needing surgery, according to a new study. The international research trial, led by Murdoch Children’s Research Institute (MCRI) and published in The Lancet Child & Adolescent Health, has showed for the first time that vosoritide treatment increases height, facial volume and the size of the foramen magnum, the hole at the base of the skull that connects the brain with the spinal cord, in children under five with achondroplasia. MCRI is the largest vosoritide clinical trial

Drug may reduce SIDS in children with achondroplasia as seen on The Hippocratic Post.